Company Overview and News

0
Bharat Forge Limited - Updates

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500493 BHARATFORG

0
Bharat Forge Limited - Shareholders meeting

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500493 BHARATFORG

0
An evening walk down Dalal Street: Global cues lift Sensex 277 pts ahead of Q1FY19 earnings

2018-07-09 moneycontrol
Equity benchmarks began the week on a strong note on Monday, gaining over 0.70 percent on positive global cues and ahead of June quarter earnings. Banks and metals stocks, and Reliance Industries, L&T and Infosys drove the market higher.
DB 500325 500820 JIPKY RELIANCE KTKBANK 532538 ASIANPAINT 532187 505283 RIGD UCLQY 500493 BHARATFORG RLNIY YESBANK INDUSINDBK KIRLPNU JPASSOCIAT UCLQF 532648 YYBKY STRTECH ULTRACEMCO 532532 SRLRY 532652 532374

0
Bharat Forge stock rises 3% after Deutsche Bank sees 31% upside

2018-07-09 moneycontrol
Bharat Forge share price rallied 3 percent intraday on Monday after global brokerage firm Deutsche Bank maintained its Buy call on the stock with a target price at Rs 830, implying 31 percent potential upside.
DB 500493 BHARATFORG

4
Over 160 stocks hit fresh 52-week low on BSE; DEN Networks, Hathway, BHEL, Andhra Bank top losers

2018-07-06 moneycontrol
The Indian benchmark indices are trading on a positive note this Friday afternoon with the Nifty adding 47 points and is trading at 10,796 mark. The Sensex is trading higher by 147 points at 35,722.
BAJAJ-AUTO 532938 CAPF 532418 532977 514034 532953 533137 VISASTEEL DEN 533644 532121 INOXWIND JBFIND VGUARD 500477 500570 BEL 500493 TATAMOTORS BHARATFORG ASHOKLEY BHQRY CONART 532721 AKLD FINOLEXIND UJAAS 501455 500940 522231 500049 GREAVESCOT 539083 DENABANK AKLS ANDHRABANK TTM

43
Closing Bell: Global weakness drags Sensex 159 pts, Nifty below 10,700; Infosys, Titan up 2%

2018-07-02 moneycontrol
IPO: Bharat Hotels, which runs five-star properties under 'The LaLiT' brand, has filed draft prospectus with capital markets regulator to garner Rs 1,200 crore through its initial share-sale. The initial public offer (IPO) comprises sale of fresh equity shares to the tune of Rs 1,200 crore, according to the draft papers filed with the Securities and Exchange Board of India (Sebi). Proceeds of the issue will be utilised towards repayment of certain loans availed by the company for other general corporate purposes, reports PTI.
523405 500325 MS.PRE MS.PRF MS.PRG ICLQY MS.PRA 512599 CADILAHC 531795 JUSTDIAL 532321 LNSTY MS GODREJCP 500493 BHARATFORG JMFINANCIL RLNIY SBAZ ANNRY TVSMOTOR GRAPHITE 524804 505192 532822 532424 JSWSTEEL VED BATAINDIA MS.PRI MS.PRK 500180 SMLISUZU AUROPHARMA ADANIENT 500228 RELIANCE 512573 533155 JUBLFOOD GDRJY 532343 535648 RIGD JBLWY HDFCBANK 509488 INDIGO AVANTI IBN ATULAUTO CDLYY 539448 ICICIBANK HDB 532174 ARBQY IDEA 500043 JSTQY

37
Market Live: Sensex off day#39;s low; Infosys, ICICI Bank, Vedanta, Bajaj Auto top gainers

2018-07-02 moneycontrol
Buzzing: Graphite India and HEG shares prices were locked at 5 percent upper circuit each for the second consecutive session after Macquarie initiated coverage on both.
BAJAJ-AUTO 500325 AUROPHARMA RELIANCE MS.PRE MS.PRF MS.PRG 532977 MS.PRA 531795 532343 RIGD LNSTY HDFCBANK MS 500493 509488 BHARATFORG RLNIY SBAZ TVSMOTOR GRAPHITE 524804 IBN TATAPOWER ATULAUTO ICICIBANK VED MS.PRI MS.PRK HDB 532174 500180 ARBQY 500102 TPCL 500400 BALLARPUR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...